Nonhuman targets in allergic lung conditions.

Abstract:

:Existing therapies for allergic asthma are far from perfect: the global prevalence of disease increases despite them and they are poorly effective in dealing with the exacerbations that account for hospitalization and asthma deaths. Commercially, there are pressures on these existing medicines too--a growing threat from generics and reluctance by payers to reimburse for increasingly marginal improvements in medicines with precedented mechanisms. Experience shows that attempts to devise selective small-molecule interventions directed at the myriad of downstream effector pathways has not been a fertile ground for the development of effective new medicines. An alternative strategy, exploiting breakthroughs in understanding the molecular basis of allergenicity and the key role of innate immune mechanisms in asthma, is to direct new approaches to the disease triggers themselves: allergens. This raises interesting possibilities for anti-Lipinski drug design (extracellular nonhuman targets, inhaled delivery) and creates unprecedented pharmacological opportunities in the therapeutic area.

journal_name

Future Med Chem

authors

Robinson C,Zhang J,Newton GK,Perrior TR

doi

10.4155/fmc.12.204

subject

Has Abstract

pub_date

2013-02-01 00:00:00

pages

147-61

issue

2

eissn

1756-8919

issn

1756-8927

journal_volume

5

pub_type

杂志文章,评审
  • Drugging the schistosome zinc-dependent HDACs: current progress and future perspectives.

    abstract::Schistosomes, like many eukaryotic pathogens, typically display morphologically distinct stages during their life cycles. Epigenetic mechanisms underlie the pathogens' morphological transformations, and the targeting of epigenetics-driven cellular programs therefore represents an Achilles' heel of parasites. To speed ...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.15.25

    authors: Marek M,Oliveira G,Pierce RJ,Jung M,Sippl W,Romier C

    更新日期:2015-01-01 00:00:00

  • An update on chemical classes targeting ERK1/2 for the management of cancer.

    abstract::Cancer, still in the limelight due to its dreadful nature, shows overexpression of multiple signaling macromolecules leading to failure of many chemotherapeutic agents and acquired resistance to chemotherapy. These factors highlight the significance of shifting toward targeted therapy in cancer research. Recently, ERK...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2019-0339

    authors: Pathania S,Rawal RK

    更新日期:2020-04-01 00:00:00

  • Design, synthesis and biological evaluation of chromenopyrimidines as potential cytotoxic agents.

    abstract:AIM:The design and synthesis of chromenopyrimidines as microtubule destabilizing agents. MATERIALS & METHODS:Novel chromenopyrimidines and chromenotriazolopyrimidines were prepared and evaluated for their cytotoxicity against MCF-7 cell line. The most potent compound was tested for its possible effect on tubulin inhib...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2017-0324

    authors: El-Bakhshawangy NM,El-Nassan HB,Kassab AE,Taher AT

    更新日期:2018-06-01 00:00:00

  • Small molecules as friends and foes of the immune system.

    abstract::Every organism is in contact with numerous small molecules (<1000 Da). Chemicals may cause or trigger adverse health effects, including diseases of the immune system. They may also be exploited as drugs. In this review, we look at the interaction between small molecules and the immune system. We discuss the hapten and...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.09.125

    authors: Kadow S,Jux B,Chmill S,Esser C

    更新日期:2009-12-01 00:00:00

  • Recent developments and advances of FGFR as a potential target in cancer.

    abstract::FGFs and their receptors (FGFRs) are critical for many biologic processes, including angiogenesis, wound healing and tissue regeneration. Aberrations in FGFR signaling are common in cancer, making FGFRs a promising target in antitumor studies. To date, many FGFR inhibitors are being detected in clinical studies, and r...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2018-0103

    authors: Xue WJ,Li MT,Chen L,Sun LP,Li YY

    更新日期:2018-09-01 00:00:00

  • Recent advances in the discovery of small molecule mTOR inhibitors.

    abstract::Mammalian target of rapamycin (mTOR) belongs to the atypical kinase family of phosphatidylinositol-3-kinase-related kinase and function as a master regulators of the switch between catabolic and anabolic metabolism. In the last decade mTOR has emerged as a therapeutic target for various diseases such as cancer, inflam...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.10.233

    authors: Roychowdhury A,Sharma R,Kumar S

    更新日期:2010-10-01 00:00:00

  • 5-azacytosine compounds in medicinal chemistry: current stage and future perspectives.

    abstract::This review summarizes the basic milestones of the research of 5-azacytosine nucleosides chronologically from their discovery and anticancer activity identification, through to subsequent unveiling of their mechanism of action based on DNA hypomethylation and tumor-suppressor gene reactivation, to the final US FDA app...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.12.36

    authors: Krečmerová M,Otmar M

    更新日期:2012-05-01 00:00:00

  • Auranofin is an effective agent against clinical isolates of Staphylococcus aureus.

    abstract::Aim: The orphan drug auranofin was recently found to exhibit antimicrobial properties. Materials & methods: We explored the efficacy of auranofin by evaluating the minimal inhibitory concentration against a collection of over 500 clinical isolates derived from multiple institutions, inclusive of drug resistant strains...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2018-0544

    authors: Tharmalingam N,Ribeiro NQ,da Silva DL,Naik MT,Cruz LI,Kim W,Shen S,Dos Santos JD,Ezikovich K,D'Agata EM,Mylonakis E,Fuchs BB

    更新日期:2019-06-01 00:00:00

  • Proteolysis-targeting chimeras mediate the degradation of bromodomain and extra-terminal domain proteins.

    abstract::Bromodomain and extra-terminal domain (BET) protein family plays an important role in regulating gene transcription preferentially at super-enhancer regions and has been involved with several types of cancers as a candidate. Up to now, there are 16 pan-BET inhibitors in clinical trials, however, most of them have unde...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2017-0264

    authors: Yang Y,Wu Z,Chen P,Zheng P,Zhang H,Zhou J

    更新日期:2020-09-01 00:00:00

  • Synthesis & antitumor activity of epothilones B and D and their analogs.

    abstract::Epothilone is a newly developed antitumor drug; its antitumor principle is to stop the cell cycle by binding to tubulin in tumor cells, promoting tubulin polymerization, inhibiting depolymerization of microtubules, and ultimately inducing apoptosis. There are many analogs of epothilone, such as epothilone B, epothilon...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2017-0320

    authors: Cheng H,Huang G

    更新日期:2018-06-01 00:00:00

  • 'Energy expenditure genes' or 'energy absorption genes': a new target for the treatment of obesity and Type II diabetes.

    abstract::Several hundred genes associated or linked to obesity have been described in the scientific literature. Whereas many of these genes are potential targets for the treatment of obesity and associated conditions, none of them have permitted the developement of an efficient drug therapy. As proposed by the 'thrifty genoty...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.10.263

    authors: Braud S,Ciufolini M,Harosh I

    更新日期:2010-12-01 00:00:00

  • Carbonic anhydrase activators.

    abstract::Mammalian carbonic anhydrases (CAs; EC 4.2.1.1) of which 16 isoforms are known, are involved in important physiological functions. Their inhibition is exploited pharmacologically for the treatment of many diseases (glaucoma, edema, epilepsy, obesity, hypoxic tumors, neuropathic pain, etc.) but the activators were less...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2017-0223

    authors: Supuran CT

    更新日期:2018-03-01 00:00:00

  • Novel anthraquinone compounds as anticancer agents and their potential mechanism.

    abstract::Anthraquinones exhibit a unique anticancer activity. Since their discovery, medicinal chemists have made several structural modifications, resulting in the design and synthesis of a large number of novel anthraquinone compounds with different biological activities. In general, anthraquinone compounds have been conside...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2019-0322

    authors: Tian W,Wang C,Li D,Hou H

    更新日期:2020-04-01 00:00:00

  • Strategies for the treatment of dengue virus infections: a narrative account.

    abstract::In comparison with other virus infections, such as HIV, HBV, HCV, influenza and herpes virus, dengue virus infections have received relatively little attention from a (chemo)therapeutic viewpoint, despite their global incidence (2.5 billion people estimated to be at risk) and absence of an effective prophylactic measu...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.10.15

    authors: De Clercq E

    更新日期:2010-04-01 00:00:00

  • Donepezil-ferulic acid hybrids as anti-Alzheimer drugs.

    abstract:BACKGROUND:Due to the complex nature of Alzheimer's disease, there is a renewed and growing search for multitarget drugs. RESULTS:Donepezil-ferulic acid hybrids (DFAHs) were prepared by the one-pot Ugi-4CR in low-to-moderate yields. DFAHs are potent antioxidant agents, showing oxygen radical absorbance capacity values...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.14.148

    authors: Benchekroun M,Ismaili L,Pudlo M,Luzet V,Gharbi T,Refouvelet B,Marco-Contelles J

    更新日期:2015-01-01 00:00:00

  • Estimation of kinetic and thermodynamic ligand-binding parameters using computational strategies.

    abstract::Kinetic and thermodynamic ligand-protein binding parameters are gaining growing importance as key information to consider in drug discovery. The determination of the molecular structures, using particularly x-ray and NMR techniques, is crucial for understanding how a ligand recognizes its target in the final binding c...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2016-0224

    authors: Deganutti G,Moro S

    更新日期:2017-04-01 00:00:00

  • Quercetin/oleic acid-based G-protein-coupled receptor 40 ligands as new insulin secretion modulators.

    abstract:AIM:Management of Type 2 diabetes mellitus by diet is achievable at the early stage of the disease; patients usually underestimate this approach and an appropriate drug therapy is required. RESULTS:Starting from quercetin and oleic acid, that have effect on insulin secretion, a small set of hybrid molecules was synthe...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2017-0113

    authors: Badolato M,Carullo G,Perri M,Cione E,Manetti F,Di Gioia ML,Brizzi A,Caroleo MC,Aiello F

    更新日期:2017-10-01 00:00:00

  • Anti-inflammatory effect of novel analogs of natural enkephalinase inhibitors in a mouse model of experimental colitis.

    abstract:AIM:The pharmacotherapy of inflammatory bowel disease is difficult and currently available treatments bring mostly poor and unsatisfactory results. RESULTS:The purpose of this work was the synthesis of opiorphin, sialorphin, spinorphin and a series of their analogs and the in vitro characterization of their effect on ...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2016-0156

    authors: Kamysz E,Sałaga M,Sobocińska M,Giełdoń A,Fichna J

    更新日期:2016-12-01 00:00:00

  • The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy.

    abstract:AIM:Currently, dozens of BRAF inhibitors and MEK inhibitors targeting RAF-MEK-ERK pathway have been introduced into clinical trials for cancer therapy. However, after 6-8 months of initial response, acquired drug resistance among the majority of those treated patients sharply diminished their clinical efficacy. DISCUS...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.14.143

    authors: Yu Z,Ye S,Hu G,Lv M,Tu Z,Zhou K,Li Q

    更新日期:2015-01-01 00:00:00

  • Proposing advancement criteria for efficient DMPK triage of new chemical entities.

    abstract::With the goal of refining our discovery DMPK workflow, we conducted a retrospective analysis on internal Celgene compounds by calculating the physicochemical properties and gathering data from several assays including solubility, rat and human liver S9 stability, Caco-2 permeability, and rat intravenous (iv.) and oral...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.13.190

    authors: Kulkarni A,Riggs J,Phan C,Bai A,Calabrese A,Shi T,Moghaddam MF

    更新日期:2014-02-01 00:00:00

  • Synthesis of quinoline derivatives as potential cysteine protease inhibitors.

    abstract::Aim: Cysteine proteases are important molecular targets involved in the replication, virulence and survival of parasitic organisms, including Trypanosoma and Leishmania species. Methodology & results: Analogs of the 7-chloro-N-[3-(morpholin-4-yl)propyl]quinolin-4-amine were synthesized and their inhibitory activity ag...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2019-0201

    authors: Andrade MM,Martins LC,Marques GV,Silva CA,Faria G,Caldas S,Dos Santos JS,Leclercq SY,Maltarollo VG,Ferreira RS,Oliveira RB

    更新日期:2020-04-01 00:00:00

  • Plant dipeptidyl peptidase-IV inhibitors as antidiabetic agents: a brief review.

    abstract::Diabetes mellitus is an increasing public health problem in the world. Type 2 diabetes is the most common type of diabetes whose complications contribute to its high death rate. It seriously impacts healthcare systems and patients' quality of life. Therefore, effective measures and new treatment strategies are needed ...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2017-0235

    authors: Turdu G,Gao H,Jiang Y,Kabas M

    更新日期:2018-05-01 00:00:00

  • Practical applications of matched series analysis: SAR transfer, binding mode suggestion and data point validation.

    abstract:AIM:The assumption in scaffold hopping is that changing the scaffold does not change the binding mode and the same structure-activity relationships (SARs) are seen for substituents decorating each scaffold. Results/methodology: We present the use of matched series analysis, an extension of matched molecular pair analys...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2016-0203

    authors: Hunt P,Segall M,O'Boyle N,Sayle R

    更新日期:2017-01-01 00:00:00

  • Butterfly structure: a scaffold of therapeutic importance.

    abstract::Graphical abstract [Formula: see text]. ...

    journal_title:Future medicinal chemistry

    pub_type: 社论

    doi:10.4155/fmc-2019-0313

    authors: Choudhary S,Silakari O

    更新日期:2020-02-01 00:00:00

  • Enhancing the pharmacokinetic/pharmacodynamic properties of therapeutic nucleotides using lipid nanoparticle systems.

    abstract::Although activity has been reported in vivo, free nucleic acid-based drugs are rapidly degraded and cleared following systemic administration. To address these challenges and improve the potency and bioavailability of genetic drugs, significant efforts have been made to develop effective delivery systems of which lipi...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.15.108

    authors: Lin PJ,Tam YK

    更新日期:2015-01-01 00:00:00

  • Ovarian cancer cells cisplatin sensitization agents selected by mass cytometry target ABCC2 inhibition.

    abstract:AIM:Cisplatin resistance in ovarian cancer remains a complex problem as tumors frequently develop resistance against drugs, a mechanism sometimes mediated by ATP-Binding Cassette transporters. Our goal was to find compounds restricting their inhibition capacity to the cisplatin efflux mediated by ABCC2 pump, among prev...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2017-0308

    authors: Comsa E,Nguyen KA,Loghin F,Boumendjel A,Peuchmaur M,Andrieu T,Falson P

    更新日期:2018-06-01 00:00:00

  • A beginner's guide to chemokines.

    abstract::This review provides an overview of chemokines and their receptors, with an emphasis on general features and nomenclature along with a short summary of their properties and functions. It is intended as an introduction to the subject and a reference point for those wishing to learn key facts about chemokines and their ...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.12.49

    authors: Vinader V,Afarinkia K

    更新日期:2012-05-01 00:00:00

  • Novel potent inhibitors of the histone demethylase KDM1A (LSD1), orally active in a murine promyelocitic leukemia model.

    abstract:BACKGROUND:Histone lysine demethylases (KDMs) are well-recognized targets in oncology drug discovery. They function at the post-translation level controlling chromatin conformation and gene transcription. KDM1A is a flavin adenine dinucleotide-dependent amine oxidase, overexpressed in several tumor types, including acu...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2017-0003

    authors: Trifirò P,Cappa A,Brambillasca S,Botrugno OA,Cera MR,Zuffo RD,Dessanti P,Meroni G,Thaler F,Villa M,Minucci S,Mercurio C,Varasi M,Vianello P

    更新日期:2017-07-01 00:00:00

  • Making way for suppressing the FGF19/FGFR4 axis in cancer.

    abstract::FGF19 is a noncanonical FGF ligand that can control a broad spectrum of physiological responses, which include bile acid homeostasis, liver metabolism and glucose uptake. Many of these responses are mediated by FGF19 binding to its FGFR4/β-klotho receptor complex and controlling activation of an array of intracellular...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2018-0099

    authors: Prieto-Dominguez N,Shull AY,Teng Y

    更新日期:2018-10-01 00:00:00

  • The promise and current status of CDK12/13 inhibition for the treatment of cancer.

    abstract::CDK12 and CDK13 are Ser/Thr protein kinases that regulate transcription and co-transcriptional processes. Genetic silencing of CDK12 is associated with genomic instability in a variety of cancers, including difficult-to-treat breast, ovarian, colorectal, brain and pancreatic cancers, and is synthetic lethal with PARP,...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2020-0240

    authors: Tadesse S,Duckett DR,Monastyrskyi A

    更新日期:2021-01-01 00:00:00